Compare Stocks: LGND, ADMA, ANIP, and GMAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.50 -0.3%	$9.27	$7.21 ▼ $20.46	$2.13B	0.78	4.24 million shs	512,873 shs
ANIP ANI Pharmaceuticals	$73.78 -0.4%	$75.80	$69.58 ▼ $97.00	$1.70B	0.45	383,222 shs	28,986 shs
GMAB Genmab A/S	$34.93 +0.3%	$31.98	$23.62 ▼ $35.66	$21.77B	0.84	1.96 million shs	1.49 million shs
LGND Ligand Pharmaceuticals	$296.04 -1.0%	$290.75	$166.10 ▼ $326.63	$5.91B	1.11	268,149 shs	31,246 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-1.86%	+6.37%	-2.06%	+8.86%	-39.21%
ANIP ANI Pharmaceuticals	-0.52%	-1.79%	-2.13%	-12.38%	-22.05%
GMAB Genmab A/S	+0.23%	+0.87%	+1.37%	+33.42%	+18.27%
LGND Ligand Pharmaceuticals	+0.21%	+5.04%	+6.15%	-1.50%	+76.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.50 -0.3%	$9.27	$7.21 ▼ $20.46	$2.13B	0.78	4.24 million shs	512,873 shs
ANIP ANI Pharmaceuticals	$73.78 -0.4%	$75.80	$69.58 ▼ $97.00	$1.70B	0.45	383,222 shs	28,986 shs
GMAB Genmab A/S	$34.93 +0.3%	$31.98	$23.62 ▼ $35.66	$21.77B	0.84	1.96 million shs	1.49 million shs
LGND Ligand Pharmaceuticals	$296.04 -1.0%	$290.75	$166.10 ▼ $326.63	$5.91B	1.11	268,149 shs	31,246 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-1.86%	+6.37%	-2.06%	+8.86%	-39.21%
ANIP ANI Pharmaceuticals	-0.52%	-1.79%	-2.13%	-12.38%	-22.05%
GMAB Genmab A/S	+0.23%	+0.87%	+1.37%	+33.42%	+18.27%
LGND Ligand Pharmaceuticals	+0.21%	+5.04%	+6.15%	-1.50%	+76.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	96.59% Upside
ANIP ANI Pharmaceuticals	2.38	Hold	$98.00	32.84% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	13.08% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	14.14% Upside

Current Analyst Ratings Breakdown

Latest LGND, ADMA, ANIP, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$345.00
9/24/2026	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$358.00
9/23/2026	ANIP ANI Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$85.00
9/23/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$390.00 ➝ $397.00
9/21/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/14/2026	ADMA ADMA Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/14/2026	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/9/2026	ANIP ANI Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$104.00
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/1/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/14/2026	LGND Ligand Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$330.00

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.17	$0.63 per share	15.00	$2.01 per share	4.72
ANIP ANI Pharmaceuticals	$883.37M	1.92	$9.41 per share	7.84	$24.03 per share	3.07
GMAB Genmab A/S	$3.72B	5.86	$1.60 per share	21.88	$9.10 per share	3.84
LGND Ligand Pharmaceuticals	$268.09M	22.02	$7.79 per share	38.01	$51.68 per share	5.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	13.58	11.17	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
ANIP ANI Pharmaceuticals	$78.34M	$4.64	15.92	8.58	N/A	11.07%	27.37%	10.47%	11/6/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	27.48	22.25	1.91	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	31.69	35.75	2.39	67.88%	20.06%	11.68%	11/5/2026 (Estimated)

Latest LGND, ADMA, ANIP, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	$2.21	+$0.17	$1.05	$260.13 million	$266.04 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
ANIP ANI Pharmaceuticals	0.99	2.91	2.41
GMAB Genmab A/S	0.81	2.46	2.44
LGND Ligand Pharmaceuticals	1.16	31.18	30.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ANIP ANI Pharmaceuticals	76.05%
GMAB Genmab A/S	7.07%
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
ANIP ANI Pharmaceuticals	8.10%
GMAB Genmab A/S	1.54%
LGND Ligand Pharmaceuticals	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
ANIP ANI Pharmaceuticals	970	22.97 million	21.11 million	Optionable
GMAB Genmab A/S	3,029	623.78 million	614.17 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable

LGND, ADMA, ANIP, and GMAB Headlines

Recent News About These Companies

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Ligand Pharma (LGND) and Compass Therapeutics (CMPX)

2 hours ago | theglobeandmail.com

Barclays Begins Coverage on Ligand Pharmaceuticals (NASDAQ:LGND)

2 hours ago | marketbeat.com

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Citigroup Analyst Says

September 25 at 1:24 AM | americanbankingnews.com

HC Wainwright Reiterates Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND)

September 24 at 12:23 PM | marketbeat.com

Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy

September 24 at 9:20 AM | rttnews.com

Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell

September 24 at 9:20 AM | finance.yahoo.com

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

September 24 at 7:00 AM | globenewswire.com

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $397.00 Price Target at Citigroup

September 23 at 11:35 AM | marketbeat.com

Sydnexis sells EMEA royalty rights to Ligand for $23 million

September 23 at 3:04 AM | streetinsider.com

Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug

September 23 at 3:04 AM | rttnews.com

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

September 23 at 3:04 AM | finance.yahoo.com

Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million

September 23 at 3:04 AM | finance.yahoo.com

Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million

September 22 at 7:00 AM | globenewswire.com

Corient Private Wealth LP Boosts Stake in Ligand Pharmaceuticals Incorporated $LGND

September 21, 2026 | marketbeat.com

Ligand Pharmaceuticals stock trades without a fresh catalyst

September 20, 2026 | ad-hoc-news.deA

Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold

September 19, 2026 | seekingalpha.com

Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

September 18, 2026 | seekingalpha.com

Baird Financial Group Inc. Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND

September 17, 2026 | marketbeat.com

Ligand Pharmaceuticals (NASDAQ:LGND) Director Martine Zimmermann Sells 1,200 Shares

September 15, 2026 | americanbankingnews.com

Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 1,200 Shares of Stock

September 15, 2026 | insidertrades.com

Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $342,000.00 in Stock

September 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND, ADMA, ANIP, and GMAB Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.49 -0.03 (-0.26%)

As of 11:35 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals NASDAQ:ANIP

$73.78 -0.27 (-0.36%)

As of 11:34 AM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Genmab A/S NASDAQ:GMAB

$34.93 +0.10 (+0.29%)

As of 11:35 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Ligand Pharmaceuticals NASDAQ:LGND

$296.04 -3.01 (-1.00%)

As of 11:34 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGND, ADMA, ANIP, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGND, ADMA, ANIP, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGND, ADMA, ANIP, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND, ADMA, ANIP, and GMAB Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

Genmab A/S NASDAQ:GMAB

Ligand Pharmaceuticals NASDAQ:LGND

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGND, ADMA, ANIP, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGND, ADMA, ANIP, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGND, ADMA, ANIP, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND, ADMA, ANIP, and GMAB Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

Genmab A/S NASDAQ:GMAB

Ligand Pharmaceuticals NASDAQ:LGND

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools